J Korean Diabetes > Volume 16(4); 2015 > Article
The Journal of Korean Diabetes 2015;16(4):242-251.
DOI: https://doi.org/10.4093/jkd.2015.16.4.242    Published online December 24, 2015.
새로운 인슐린 제제와 인슐린 투여법에 대한 임상적 적용
임태석, 고승현
Clinical Use of New Insulins and New Insulin Delivery Systems.
Tae Seok Lim, Seung Hyun Ko
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. kosh@catholic.ac.kr
Insulin plays an important role in the treatment of diabetes. Since it was discovered in the early 1920s, major advances have been made in the medical use of insulin. However, certain insulin associated challenges remain, such as hypoglycemia, weight gain, complex management, and injection site pain. Novel insulins and delivery systems are being developed that can address these limitations. Insulin degludec is a novel basal insulin with a long half-life (25 hours) and action duration (> 42 hours). Glargine U300 is a concentrated formulation of insulin glargine. For improvement in postprandial glucose control, ultrarapid-acting insulins are being investigated. New insulin delivery systems including inhaled insulin and insulin patches are also being developed to overcome the inconvenience associated with subcutaneous injection. In this review, clinical studies of new insulins and new insulin delivery systems are summarized.
Key Words: Diabetes mellitus, Insulin, Insulin delivery system
METRICS Graph View
  • 0 Crossref
  •  0 Scopus
  • 1,365 View
  • 19 Download
Related articles

Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2024 by Korean Diabetes Association. All rights reserved.

Developed in M2PI

Close layer